Tests modified immune cells in children with relapsed neuroblastoma or osteosarcoma
Tests patient T cells engineered to target GD2 in neuroblastoma or osteosarcoma.
Key facts
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Where
- Atlanta and Chapel Hill, United StatesSee the 2 sites
- Trial code
- Registry title
- Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 18 people, planned
- Started
- 19 Feb 2019
- Expected to end
- 19 Jun 2044
- Type of study
- Interventional
- Treatments tested
- iC9.GD2.CAR.IL-15 T-cells
- Cyclophosphamide
- Fludarabine
- Record updated
- 27 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults whose neuroblastoma or osteosarcoma has come back or has not responded to standard treatment, and who have disease that can be measured.
- Age
- 18 months or older. The record gives no upper age limit.
- Sex
- Anyone can join, men and women.
- Disease stage
- High-risk neuroblastoma that persists, did not respond, or has relapsed, or osteosarcoma that has relapsed or does not respond to standard treatment. Disease must be measurable or evaluable.
- Earlier treatment
- Neuroblastoma: relapse after intensive multi-drug first-line treatment, or progression during it, or less than a complete response after at least 4 cycles of multi-drug chemotherapy.
Main reasons for not taking part
- Pregnant or breastfeeding
- Another active cancer that needs treatment
- Known central nervous system disease
- Seizure disorder that needs seizure medicine
- Past allergic reaction to mouse protein products, cyclophosphamide or fludarabine
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Written HIPAA authorization signed by legal guardian
- Adequate performance status as defined by Lansky or Karnofsky performance status of ≥ 60 (Lansky for <16 years of age)
- Life expectancy ≥12 weeks
- Histological confirmation of neuroblastoma or ganglioneuroblastoma at initial diagnosis. Bone marrow samples are acceptable as confirmation of neuroblastoma, confirmation of osteosarcoma at diagnosis
- High-risk neuroblastoma with persistent/refractory or relapsed disease, defined as:; First or greater relapse of neuroblastoma following completion of aggressive multi-drug frontline therapy; First episode of progressive neuroblastoma during aggressive multi-drug frontline therapy. Persistent/refractory neuroblastoma as defined by less than a complete response by the revised International Neuroblastoma Response Criteria (INRC) at the conclusion of at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol (such as A3973 or ANBL0532); Patients must be diagnosed with high risk neuroblastoma at initial diagnosis or if non-high risk at time of initial diagnosis must have had evidence of metastatic progression when >18 months of age as defined in the protocol or relapsed or refractory osteosarcoma that is not responsive to standard treatment
- Measurable or evaluable disease per Revised INRC for subjects with neuroblastoma or measurable disease by Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1 criteria for subjects with osteosarcoma
- Adequate central nervous system function as defined by:; No known Central Nervous System ( CNS) disease; No seizure disorder requiring antiepileptic drug therapy
Who cannot take part
- Has a known additional malignancy that is active and/or progressive requiring treatment
- History of hypersensitivity reactions to murine protein-containing products
- History of hypersensitivity to cyclophosphamide or fludarabine
- Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Other criteria
- All clinical and laboratory data required for determining eligibility must be available in the subject's medical/research record which will serve as the source document
- Because of the nature of iC9.GD2.CAR.IL-15 T cell product preparation, subjects will be assessed for initial study enrollment eligibility (prior to cell procurement) and then will have to meet criteria prior to starting lymphodepletion and prior to T cell infusion
Where in United States
- Emory Winship Cancer InstituteAtlanta, United StatesNo longer taking part
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel HillChapel Hill, United StatesContact: Catherine ChengTaking people
About the trial
What the trial wants to find out
The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. Antibodies work by sticking to those bacteria or substances, which stops them from growing and causing bad effects. T cells are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been enough to cure most patients.
Read full original descriptionShow less
This multicenter study is designed to combine both T cells and antibodies in order to create a more effective treatment. The treatment that is being researched is called autologous T lymphocyte chimeric antigen receptor cells (CAR) cells targeted against the disialoganglioside (GD2) antigen that express Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9), also known as iC9.GD2.CAR.IL-15 T cells.
The group in the trial
- iC9.GD2.CAR.IL-15 T-cellsTreatment being tested
The continuous reassessment method (CRM) will be used to estimate the maximum-tolerated dose (MTD) of cells that to be given in dose escalation cohorts comprised of 2-6 subjects. The final MTD will be the dose with estimated probability of dose limiting toxicity (DLT) closest to the target toxicity rate of 20%. Three cell doses will be evaluated: 0.5 x 10\^6 cells/kg, 1.0 x 10\^6 cells/kg, 1.5 x 10\^6 cells/kg. Cohort enrollment will be staggered and each subject must complete at least 2 weeks of the cell treatment without incident of DLT before another subject can be enrolled at that dose level. A minimum of two subjects must complete the 4-week post-infusion DLT period before enrollment at the next higher dose level will be considered. If dose level 1 is determined to be above a tolerable dose, de-escalation would occur to dose level -1 where subjects would receive 0.25 x 10\^6 cells/kg.
Treatment: iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, and Fludarabine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase I Study of Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients With Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
- Plain-language title
- Tests modified immune cells in children with relapsed neuroblastoma or osteosarcomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 March 2026